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Abstract
Microglia/macrophage activation has been associated with the pathogenesis of various
neurological diseases including human immunodeficiency virus encephalitis, transmissible
spongiform encephalitis, and Alzheimer’s disease (AD). In vitro studies have indicated a role for
TNFα in activating these cells which leads to their migration, proliferation, and secretion of
proinflammatory cytokines and chemokines that may potentially damage brain tissue. In the
current study, we analyzed the phenotype of microglia and macrophages enriched from wild type
and TNFα deficient mice infected with a neurovirulent murine retrovirus. Although TNF
receptors CD120a and CD120b were expressed on both microglia and macrophage population,
unaltered by either retrovirus infection or TNFα deficiency. To determine if hindering
microglia/macrophage activation and TNFα expression during an established viral infection
would impede the development of neurological disease, we treated mice with minocycline which
has been reported to inhibit both microglia activation and TNFα production. Despite the
decreased expression of certain genes involved in TNF signaling and microglia/macrophage
activation, there was no delay in onset of neurological disease between PBS and minocycline
treated EC infected mice. mRNA expression for accessory molecules involved in the TNF
Superfamily signaling was significantly reduced with minocycline treatment. Understanding how
to better manipulate these pathways could lead to ways to decrease the severity of neurological
disease in not solely this model but others in which they has been directly linked to pathogenesis.

vi

Chapter 1: Introduction
HIV infection of the central nervous system is observed in 80% of those infected with
HIV, spreading presumably by infected monocytes, macrophages or T cells. However, only 20%
of HIV infected individuals develop neurological disease1. The cytokine tumor necrosis factoralpha (TNFα) has been implicated in disease progression in patients suffering from HIVassociated dementia2, based on studies involving gene expression of patients with and without
dementia3,4. However, the mechanism by which TNFα is acting in pathogenesis has yet to be
elucidated. In a study involving a neurovirulent retrovirus, animals deficient in TNFα had either
delayed disease or no symptom presentation when infected5, indicating a role for TNFα in
pathogenesis. In the same study, decreased expression of the microglia/macrophage activation
marker F4/80 was also observed in infected TNFα deficient animals when compared to infected
wild type animals, indicating the lack of TNF may be having an effect on microglia/macrophage
activation5.
Microglia can be activated by direct interaction with viruses, bacteria, or cytokines2,6,7.
Activation of these cells leads to their migration, proliferation, and secretion of TNFα and IL-1β
and other proinflammatory cytokines and chemokines which may potentially damage brain
tissue8. Therefore, we hypothesize that TNFα may be important for the activation of
microglia/macrophages during retroviral pathogenesis in the brain. In the present study, we
analyzed the effect of TNFα on the microglia and macrophage response to retrovirus infection in
the brain using a mouse model of polytropic retrovirus infection. We enriched microglia and
macrophages from retrovirus infected wild type (WT) and TNF-/- mice to analyze the activation
state of these cells during infection. In addition, we treated EC infected mice with the microglia
activation inhibitor minocycline to determine if administration after the establishment of a
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productive viral infection influenced the onset of neurological disease that may be attributed to
microglia activation and TNFα secretion.
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Chapter 2: Review of Literature
2.1: Tumor Necrosis Factor-Alpha (TNFα)
First observed in the mid 1800s, TNFα has long been associated with immunological
function and more recently pathogenesis. TNFα belongs to a family of structurally related
molecules that are involved in cell signaling and immune responses. TNFα is produced by
numerous cell types including natural killer cells, monocytes/ macrophages, and lymphocytes.
TNFα is initially synthesized and expressed as a transmembrane molecule, the extracellular
portion of which is subsequently cleaved by TNFα converting enzyme (TACE) to release the
soluble 17 kDa molecule9. Originally, it was believed that TNFα was more potent in its soluble
form, but current studies indicate that the membrane bound form has a crucial role in cell to cell
signaling whereas the soluble form of the cytokine may be more involved in apoptosis10.
2.2: TNFα and Neurological Disease
TNFα upregulation has been associated with the pathology of many neurological diseases
including multiple sclerosis (MS)11, Alzheimer’s disease (AD)12, transmissible spongiform
encephalopathy 13-15 and HIV associated dementia 2,16-18, but the exact mode in which TNFα
contributes to disease in vivo has yet to be established. TNFα and TNF- receptor (TNFR)
neutralization studies have met with mixed success11. In a study involving a TNFR1 blocking
agent to treat the symptoms of MS, most patients reported reduced symptoms, but some
experienced exacerbations during the trial11,19. In an extreme case, the systemic anti TNFα
treatment induced symptoms similar to lupus in trial participants20.
2.3: TNFα and Human Immunodeficiency Virus associated Dementia
TNFα involvement may contribute to the pathogenesis of HIV in the brain. For example,
the TNFα 308 allele had a much greater occurrence in those suffering with HAD, suggesting the
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potential for a genetic predisposition to developing the disease21. The distribution of apoptotic
neurons in HIV patients was closely associated with the presence of activated microglia16.
Reports of elevated levels of TNFα and TNFR expression in microglia/macrophage isolated from
individuals suffering from HAD3 suggest that soluble factors released by these activated cells
may be important in mediating neurotoxicity. The finding that neurons have the pro-apoptotic
TNFR1 on their cell surface supports the hypothesis that TNFα secreted by activated microglia
or macrophages may induce neuronal apoptosis3. Immunohistochemical analysis of brain tissue
from patients with HAD displayed a correlation between severity of disease and TNFα and
NFκB expression16. TNFα also serves to stimulate the release of excitatory amino acids (EAAs),
most notably L- cysteine, which may act to stimulate neuronal apoptosis via N-methyl-Daspartate receptors (NMDARs)22.
2.4: TNF Superfamily Receptors and Signaling
TNFα binds to two receptors: CD120a (p55-R, TNF-R-I p55, TNF-R, TNFR1, TNFAR,
TNF-R55, p55TNFR, TNFR60, Tnfsfr1a) and CD120b (p75, TNF-R, TNF-R-II, TNFR80,
TNFR2, TNF-R75, TNFBR, p75TNFR). The receptors are single transmembrane glycoproteins
with 28% homology mainly residing in their extracellular domain consisting of four tandemly
repeated cysteine-rich motifs10. They are coexpressed on the surface of most cell types, with the
smaller CD120a associated with the traditional TNFα associated inflammatory responses and
apoptosis whereas the CD120b receptor has been implicated in T cell apoptosis, TNFα induced
skin necrosis, and thymocyte proliferation23. The CD120a:CD120b expression ratio of a certain
cell may predetermine the response of the cell to TNFα.
CD120a serves to recruit TNFR1 associated death domain protein (TRADD) which can
in turn recruit receptor interacting protein-1 (RIP1) or Fas-associated death domain protein
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(FADD) (fig. 1) (rev in 17). RIP1 interacts with antiapoptotic proteins which serve to activate the
MAP kinase pathways ultimately leading to the activation of the transcription factor NFκB.
Thus activated, NFκB aids in promoting cell survival. Conversely, the interaction of FADD with
TRADD recruits pro-caspase 8, thus forming the death- inducing signaling complex (DISC).
This cleaves the caspase, thereby forming its active form which triggers the downstream
activation of effector caspases 24 which will subsequently lead to cell death.

Figure 1: Signaling pathways of CD120a (TNFR1) and CD120b 25. Taken from
http://www.biotechjournal.com/Journal/jan %202002/jan Article 6text.htm
Activation of the other TNFα receptor CD120b initially leads to the recruitment of
TRAF2 (fig. 1) (rev. in 17). Ultimately, the downstream action of this is to activate NFκB and
promote cell survival. Certain limitations exist when studying signal transduction via CD120b.
Upon activation the receptor is readily autolytically cleaved from the cell surface. Possibly, the
cleaved form may serve a decoy function26. In this soluble form, CD120b retains the ability to
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bind cytokine. The membrane form of TNFα has a much higher affinity for CD120b, indicating
that this receptor may play an important role in cell to cell communication rather than apoptosis.
Although TNF does not signal through CD95, TNFR1 and CD95 share a similar signal
transduction pathway that can interact with each other. CD95 (FAS, APO-1, APT1, Tnfsfr6) is
synthesized as a transmembrane protein that forms a trimeric complex to induce signaling (rev.
in 26). CD95 is expressed on a variety of cell types while CD95L expression is restricted to
immune cells including NK cells and activated T cells. Similar to TNFR1, CD95 contains a
death domain (DD) which allows adaptor proteins to dock and initiate signaling. One such
protein is CD95-associated protein with DD (FADD), which interacts with Daxx to initiate
apoptotic signals by activating caspase cascades or other pathways. In addition, alternative
splicing of the CD95 mRNA will produce decoy receptors that lack the DD and thereby inhibit
CD95 mediated signaling. CD95 and CD95L have been reported to be elevated in several
neurological conditions including retrovirus neurodegeneration, Alzheimer’s, Huntington’s, and
Parkinson’s disease27-30.
2.5: Microglia/Macrophages and TNFα
One of the ways in which TNFα may be involved in neurological disease is through its
ability to activate mircoglia31. The presence of TNFα correlates with microglia/macrophage
activation or recruitment31. The secretion of TNFα early in spinal cord injury may be involved in
autoactivating microglia/macrophages32. Studies indicate a role for TNFα in accentuating
monocyte/ macrophage recruitment to sites of viral infection33, potentially spreading the virus
within the brain if the cells are actively infected. A study involving TNFα knockout mice
reported decreased mRNA expression of the microglia/macrophage activation marker F4/80
during neurovirulent retroviral infection as compared to wild type controls5. This lack of
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activation may have slowed or completely halted disease progression in these animals, for only
15% of animals infected developed neurological symptoms5. Therefore, elucidating this detailed
activation process may give researchers more insight into how to halt or delay this process and
potentially hinder activated microglia/macrophage induced neurological disease.
2.6: Microglia
Microglia cells support and protect neurons and serve to facilitate the innate immune
response within the CNS. In the brain, there are two distinct types of cells hailing from the
hemopoietic lineage: parenchymal microglia, perivascular or meningeal macrophages. Microglia
perform tasks including maintenance of homeostasis, production of nerve growth factors and
neurotrophins thus aiding in the removal of dead cells and the regeneration of damaged
neurons18. Under normal conditions, parenchymal microglia are present in a ramified or highly
processed form where they have low phagocytic and endocytic activity. When resting, they
interact with astrocytes and neurons in signaling and support. Activation causes them to retract
their processes and shift into a more amoeboid or macrophage-like morphology34,35. In addition
to morphology modifications, gene expression profiles of activated microglia also change8,36-38
with recent evidence suggesting that these alterations are stimulus specific38. Acquired functions
of activated microglia include increased expression of innate immune cell surface receptors
including Fc receptors and pattern recognition, proliferation, migration, and increased secretion
of proinflammatory mediators including TNFα and IL-1β, as well as generation of reactive
oxygen intermediates and nitrogen intermediates39. This microglia/macrophage activation may
potentially precede neuronal death, which was demonstrated in experiments showing that
apoptosis in neurons was found following the activation of microglia during prion disease40.
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Cell surface markers have proven useful in differentiating activated from resting
microglia5. Microglia have been molecularly phenotyped using cell surface markers. For
example, F4/80, CD11b/c and CD45 are commonly used to identify and describe microglia5,41-43.
F4/80 can be used to determine the degree of microglia activation for it is upregulated upon
activation44. Additionally, ionized binding calcium adapter molecule (Iba1) has been used as a
general marker for immunohistichemical identification of microglia45,46. The expression level of
CD11b (Mac-1) and CD45 differ based upon the state of activation. CD45 is also used to
identify macrophages, but the expression of this marker by microglia is approximately one half
that of tissue macrophages47 allowing this marker to be used to differentiate between CD45hi
CD11b+ macrophages and CD45lo CD11b+ microglia43.
2.7: Microglia/Macrophages and Retrovirus Infection
The principal pathogenesis of HAD appears to involve the response of microglia and
infiltrating macrophages. Early in disease, few microglia are productively infected with HIV
whereas later in disease the majority of infected cells tend to be parenchymal microglia48. In
HAD patients, microglia are proposed to serve both a neuroprotective and potentially
neurodegenerative role. When retrovirus replication occurs in the brain, it can activate
macrophages and microglia leading to the upregulation of adhesion molecules and chemokines in
the microvascular endothelial cells thereby further breaking down the blood brain barrier and
allowing for increased cellular traffic into the brain49. Microglia can be activated by the virus
itself, by indirect immune stimulation, or by interacting with secreted viral proteins50. Microglia
activation leads to an upregulation of their effector molecule production many of which may
potentially harm the brain. Proinflammatory cytokines, proteases, excitatory amino acids and
oxide radicals released by microglia may serve to damage CNS tissue51. Therefore,
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understanding the signaling involved in microglial activation is crucial for the development of
therapeutics for the treatment and prevention of HAD.
2.8: Microglia and Other Neurological Diseases
In addition to HAD, microglial involvement or activation has been associated with the
pathology of many neurological diseases including AD, MS, and TSE. Microglia cultured from
patients suffering from AD show increased chemotaxis towards beta- amyloid protein plaques,
and increases in both activation and phagocytic activity52. During the early stages of MS,
microglia display increased proliferative and lysosymal activity53. During TSE infection,
infected microglia display phenotypic changes and distinct pattern of inflammatory molecular
changes38.
2.9: Inhibition of Microglia/macrophage Activation
Minocycline (7-Dimethylamino-6-demethyl-6-deoxytetracycline) is part of the
tetracycline family of antibiotics, sharing broad spectrum antibiotic capabilities54. Tetracyclines
act upon bacteria by inhibiting protein synthesis (for a rev., see Ref. 55). Minocycline is
structurally different from the basic tetracycline in the location of a single amino group (Fig. 2).
In humans, the drug is either administered orally or intravenously with dosage recommendations
the same for either route whereas researchers in animal studies usually inject it intraperitoneally
for in vivo testing54,56. The drug is rapidly and readily absorbed leading to less disruption of the
natural gastrointestinal flora54. A distinct advantage of minocycline is its lipophilic nature,
thereby enhancing diffusion into the tissue, including the brain57. Minocycline has been shown
to interfere with inflammatory responses due to its role in hindering microglia activation.
Recently, minocycline has been reported to interfere with inflammation in Alzheimer’s
Disease58, global and focal ischema58,59 certain models of Huntington’s disease60-62, and
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Tetracycline

Minocycline

Figure 2: The structure of minocycline differs from that of a basic tetracycline in a single amino
group55.
simian immunodeficiency virus63. In most of these cases, activation of microglia was also
severely inhibited57-59,63-66, thereby reducing the release of iNOS, NADPH oxidase, and
inflammatory mediators including cytokines and chemokines, including TNFα2. In certain
animal models of Huntington’s disease, release of caspases-1 and -3 was reduced potentially
interfering with apoptosis. In addition, cytochrome c release from mitochondria was also
decreased when animals were treated with the drug56. A recent report illustrates minocycline’s
ability to inhibit TNFα expression in mixed glia cultures and promote neuronal survival64.
Researchers have recently reported that minocycline proved useful in attenuating or potentially
inhibiting encephalitis in a macaque model of SIV63. The same study also revealed a significant
decrease in levels of monocyte chemoattractant protein-1 67 as measured by enzyme-linked
immunosorbent assay in animals treated with minocycline63.
2.10: Murine Model
Certain fields of science have grown tremendously through the use of an animal model to
study biological effects. Cell culture models may mimic the activity of a certain cell type, but
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they cannot truly match the response achieved in the dynamic environment of living tissue. The
murine model allows for the manipulation of the host genetics in order to determine the role of
specific gene products in disease progression.
Murine leukemia viruses 27 are a group or retroviruses that induce a number of diseases.
Polytropic retroviruses induce a neurological disease consisting of tremors of the hind limbs,
ataxia, and seizures5,68. Polytropic retroviruses differ from the more commonly studied ecotropic
retroviruses in that their envelope protein binds to xenotropic polytropic receptor- 1 (XPR1) as a
cellular receptor rather than cationic amino acid transporter-1 (CAT-1) used by ecotropic
viruses69. The envelope protein has been shown be a factor in mediating neurological disease.
For example, the Fr98 virus was initially constructed by inserting a portion of the polymerase
and the entire envelope gene of a neurovirulent virus 70 into the non-neurovirulent FB29 virion71.
Fr98’s envelope gene contains two separtate neurovirulent determinants: between the EcoRI to
ClaI (EC)and the BbsI to EcoRI (BE) restriction enzyme digestion sites70 (Table 1). All viruses
infect the same cell types including microglia and endothelia and are present in similar regions of
the brain70,71.
The EC region of the Fr98 envelope gene is known to induce the same neurological
symptoms as Fr98, but with slower progression and decreased incidence5. Increased expression
of proinflammatory cytokines and chemokines are associated with this model of neurological
disease72. The lack if lymphocyte infiltration seen in this model suggests that the innate immune
system is responsible for the chemokine/ cytokine changes. The characteristic pathology
associated with this disease is activation of astrocytes and the activation or recruitment of
macrophages/ microglia72. EC infection leads to an upregulation of TNFα in infected wild type
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Figure 3: A depiction of the virus genomes for the parent and chimeric strains with
corresponding incidence of neurological disease in 129SvEv mice72.
animals, indicating a role for the presence of TNFα in EC induced pathogenesis. In 129SvEv
mice, disease presented as early as day 20 with 50% clinical by day 25 post infection and with
79% of animals becoming clinical by the termination of the study5. EC virus infection in TNF-/animals induced disease in 15% of animals by the termination of the study.
Microglia/macrophage activation, as measured by F4/80 mRNA expression, was dramatically
decreased in EC infected TNF-/- animals5 indicating that the presence of TNFα may be
necessary for microglia/macrophage activation during EC infection. In the current study, we
analyzed how decreased or an absence of TNFα influences microglia/macrophage activation and
TNFα signaling.
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Chapter 3: Materials and Methods
3.1 Solutions
10x Phosphate buffered saline (PBS)
26.8 g Sodium phosphate, dibasic
13.8 g Sodium phosphate, monobasic
75.6 g Sodium chloride
Dissolve in 800 ml ddH2O
Adjusted pH to 7.0.
Brought to 1L with ddH2O.
Stored at room temperature (RT).
1x PBS
100 ml 10x PBS
900 ml ddH2O
Mixed completely and stored at RT.
10x Tris buffered saline (TBS)
24.2 g Tris base
87.7 g Sodium chloride (NaCl)
Dissolve in 800 ml ddH2O
Adjusted pH to 7.5.
Brought to 1 L with ddH2O.
Stored at RT.
1x TBS
100 ml 10x PBS
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900 ml ddH2O
Mixed completely and stored at RT.
0.1 M Citric Acid
1.92 g Citric acid, anhydrous
100 ml ddH2O
Mixed completely and stored at RT.
0.1 M Sodium citrate, dihydrate
14.7 g Sodium citrate
500 ml ddH2O
Mixed completely and stored at RT.
Citrate Buffer Antigen Retrieval Working Solution
9 ml of 0.1 M Citric acid
41 ml of 0.1 M Sodium citrate, dehydrate
Bring to 500 ml with ddH2O.
Bring pH to 6.0.
Mixed completely and stored at RT.
Normal Donkey Serum Blocking Solution
2 ml donkey serum (Sigma)
1ml BSA (Sigma)
0.1 ml cold fish skin gelatin (Sigma)
0.1 ml Triton X-100 (Sigma)
0.05 ml Tween 20 (Bio-Rad)
98 ml 1x PBS
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Mixed well and stored at 4oC.
DAPI Concentrated Stock Solution (5mg/ml or 14.3 mM)
10 mg 4',6-Diamidino-2-phenylindole (DAPI) (Invitrogen)
2 ml Dimethylformamide (DMF) (Fisher)
Vortexed to mix.
Aliquotted and stored at -20oC.
DAPI Working Solution (100ng/ml or 300nM in PBS):
2 µl DAPI Stock Solution
100 ml PBS
Wrapped bottle in foil to prevent light penetration. Stored at 4oC.
70% Percoll
70 ml Percoll (Sigma)
10 ml 10x PBS
20 ml ddH2O
Mixed well and stored at 4oC.
37% Percoll
37 ml Percoll
10 ml 10x PBS
53 ml ddH2O
Mixed well and stored at 4oC.
30% Percoll
30 ml Percoll
10 ml 10x PBS
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60 ddH2O
Mixed well and stored at 4oC.
2% BSA/PBS
2 g bovine serum albumin (Sigma)
100 ml 1x PBS
Let the BSA sit on top of the PBS to dissolve. Mixed well and stored at 4oC.
2% BGS/PBS
2 ml Bovine growth serum (BGS) (Biomeda)
98 ml 1x PBS
Mixed well and stored at 4oC. Discard when solution appears cloudy.
0.5% FSG/TBS
5 ml cold fish skin gelatin (Sigma)
1 L 1 x TBS
Mixed well and stored at 4oC. Discard when solution appears cloudy.
1% saponin/10xPBS
0.5 g saponin (Sigma)
50 ml ddH2O
Let the saponin sit on top of the PBS to dissolve. Mixed well and stored at 4oC.
0.1% saponin/PBS
5 ml 1% saponin/10xPBS
45 ml ddH2O
Mixed well and stored at 4oC.
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2% Paraformaldehyde/PBS
2 g paraformaldehyde (Sigma)
100 ml 1x PBS
Dissolve at 56oC while shaking.
Will take some time to dissolve. Mixed well and stored at 4oC.
3.2: Antibody Information
Table 1: Information detailing primary antibody antigens, isotypes, source and concentration
used in this study.
Antigen
CD11b

Clone
M1/70

CD11c
CD14

HL3
mC5-3

CD16/CD32

2.4G2

CD45

30-F11

CD45

30-F11

CD80

16-10A1

CD86
CD120a
CD120b
F4/80
F4/80
CD68
CD4

GL1
HM104
HM102
BM8
BM8
FA-11
RM4-5

CD8

53-6.7

Isotype
Rat IgG2b, κ
Armenian Hamster
IgG1, λ2
Rat (LOU) IgG1, κ
Rat (SpragueDawley) IgG2b, κ
Rat (LOU/Ws1/M)
IgG2b, κ
Rat (LOU/Ws1/M)
IgG2b, κ
Armenian Hamster
IgG2, κ
Rat (Louvain),
IgG2b, κ
Rat IgG2a
Rat IgG2a
Rat IgG2a, κ
Rat IgG2a, κ
Rat IgG2a
Rat (DA) IgG2b, k
Rat (LOU/Ws1/M)
IgG2b, κ

gp70
Iba-1

n/a
n/a

Goat polyclonal
Rabbit polyclonal

Vendor
BD Pharmingen

Conjugation
PE

Concentration
0.2 µg/ml

Working
Dilution
1:1000

BD Pharmingen
BD Pharmingen

FITC
FITC

5 µg/ml
5 µg/ml

1:200
1:200

BD Pharmingen

n/a

0.5 µg/ sample

1:200

BD Pharmingen

FITC

5 µg/ml

1:200

BD Pharmingen

PerCP

5 µg/ml

1:200

BD Pharmingen

PE

5 µg/ml

1:200

BD Pharmingen
Serotec
Serotec
eBioscience
eBioscience
Serotec
BD Pharmingen

PE
R-PE
R-PE
FITC
APC
n/a
R-PE

5 µg/ml
10 µl/sample
10 µl/sample
2.5 µg/ml
2.5 µg/ml
10 µg/ml
5 µg/ml

1:200
1:10
1:10
1:200
1:200
1:100
1:200

BD Pharmingen
Rocky Mountain
Labs
Wako Scientific

R-PE

5 µg/ml

1:200

n/a
n/a

n/a
2.5 µg/ml

1:500
1:200

3.3: Mouse Strains
129S6, (129SvEv), mice were purchased from Taconic (Hudson, NY). TNF-/- and wildtype controls (129S6) were kindly provided by Francis Balkwill and have been previously
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described 73. Animals were bred and maintained at the Louisiana State University School of
Veterinary Medicine vivarium. All animal experiments were carried out under the guidance of
Louisiana State University’s Animal Care and Use Committee and the guidelines set forth by the
National Institutes of Health.
3.4: Virus Infection
The construction of virus clone EC has been described previously 70. Virus stocks were
obtained from cell culture supernatants of cultured EC infected Mus dunni cells. Viral titers
were determined by focus forming assays using the monoclonal antibody 720 which recognizes
the viral envelope protein70,74. Neonates were inoculated within 24 hours of birth with 104 focus
forming units (FFU) of EC in 100 µl of cell culture medium by intraperitoneal injection using a
27 ½ gauge needle and 1 ml syringe (Becton Dickinson, Franklin Lakes, NJ). Animals were
observed daily for overt signs of clinical disease which was characterized by tremors of the hind
limbs, ataxia and seizures. At the onset of neurological disease or at the appropriate time point,
animals were euthanized under deep Isofluorane anesthesia followed by exsanguination with an
axillary incision. Brains and spleens were removed and divided in half sagittally with half
immersion fixed in 3.7% neutral buffered formalin (NBF) for 48 hours and kept in 70% ethanol
until histological processing and the other half flash frozen in liquid nitrogen and stored at -80oC
for RNA isolation. For microglia enrichment, brains were removed and placed in ice cold 2%
bovine growth serum (BGS)/ 1xPBS (2%BGS/PBS) in one well of a six well plate and kept on
ice.
3.5: Minocycline Treatments
Litters of 129S6 were randomly assigned to one of four groups and inoculated as
mentioned above. The four groups were as follows: mock infection and phosphate buffered
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saline (PBS) treatment, mock infection and minocycline treatment, EC infection and PBS
treatment, and EC infection and minocycline treatment. Starting on day 14 post infection and
continuing every other day until the termination of the study, litters were weighed on a digital
scale (Ohaus, Pine Brook, NJ) and injected with 35 mg of minocycline per kg of body weight in
PBS for a total volume of 20 µl per animal. Animals were weighed at each injection until they
reached a constant weight at which point they were weighed weekly. Minocycline was
administered with a single intraperitoneal injection using a 29 gauge insulin syringe (BD).
Animals were monitored daily for signs of neurological disease and euthanized as described
above.
3.6: Enrichment of Microglia
Prior to each experiment, Percoll step gradients were generated to contain 2.5 ml 30%
and 2.5 ml 37% layers in 15 ml tubes. In some experiments, trypan blue (0.04% trypan/37%
Percoll) and/or phenol red (0.4% Phenol red/70% Percoll) (Sigma, St. Louis, MO) were added to
more readily define the layers. At the appropriate time post infection, brains were removed and
kept on ice until processing.

Tissues were disrupted in a sterile glass dounce homogenizer

using 7-9 strokes. The homogenate was removed with a sterile transfer pipette and placed in a
sterile 15 ml tube (Biologix), the homogenizer washed with approximately 6 ml of ice cold PBS
and added to the original homogenate. Samples were centrifuged at 1500 rpm for 10 minutes at
4oC, supernatants were poured off, and the pellet was resuspended in 5 ml 70% Percoll/ 1xPBS.
The homogenate was pipetted under two pre-made 30%/ 37% Percoll gradient and centrifuged at
500 x g for 20 minutes at room temperature with no brake. Lesser dense brain tissue migrated to
the upper levels of the gradient and was discarded. The cells between the 37%/ 70% layer were
collected and pelleted at 1500 rpm for 10 minutes at room temperature. Any remaining
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erythrocytes were lysed with red blood cell lysis buffer (Sigma) for five minutes, and the cells
were repelleted for the same speed and time. Cells were then resuspended in 2% bovine serum
albumin (BSA) (Sigma) + 1x PBS (2%BSA/PBS) and placed on ice until needed. For
experiments determining the microglia to macrophage ratio in the brain, individual animals were
assayed. Phenotypic analysis was performed using cells pooled from littermates.
3.7: Immunofluorescent Cell Staining
Cells were placed in every other well of a Costar 96 well cell culture plate (Corning) and
centrifuged at 1500 rpm for 7 minutes at room temperature. Cells were blocked for at least five
5 minutes at room temperature in 0.25 µg of anti-mouse CD16/CD32 (Fcg III/II Receptor) (BD
Pharmingen) diluted in 25 µl 2%BSA/PBS. 75 µl of the appropriately diluted antibody
combination was added to each well and incubated for at least 20 minutes at 4oC in the dark (for
details, see Table 1). After incubation, cells were centrifuged and washed twice in 200 µl
PBS+BSA. Cells were either assayed fresh or fixed in 2% paraformaldehyde/ PBS and kept at
4oC until analysis.
For intracellular antigen staining, fixed cells were pelleted as mentioned previously and
washed twice in PBS. Cells were resuspended in 200µl of 0.1% saponin/1xPBS and incubated at
room temperature for between 10- 20 minutes to perforate the cell membrane. After washing in
0.1% saponin/PBS, samples were incubated with 50 µl of rat anti-CD68 (Serotec, Raleigh, NC)
diluted in 0.1% saponin/ PBS and incubated at 4oC for at least 20 minutes. After one wash, 50 µl
of PE conjugated anti-rat IgG (Caltag) in 0.1% saponin/ PBS was added to the samples and
incubated for 20 minutes at 4oC. Cells were washed twice, resuspended in PBS and kept at 4oC
until analysis.
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3.8: Flow Cytometry
Flow cytometric analysis was performed on a FACSAria or FACScan (BD Biosciences)
using FACSDiva or Cell Quest Software (BD Bioscience). FlowJo (Treestar) software was used
for post- acquisition analysis. In initial experiments, ViaProbe (BD Bioscience) staining was
used to gate upon the live cells. Forward versus side scatter plots were used to exclude debris
and doublet events. Microglia and macrophage populations were identified by their relative
expression of CD45 and F4/80. The expression level of CD45 differs between microglia and
macrophages which can be used distinguish between these two cell types75,76. Due to the
common nature of CD45 expression on a number of various cell types, we used the specific
macrophage/ microglia marker F4/80 to identify these cell types. For the purposes of this study,
populations referred to as microglia are CD45lowF4/80+, and those referred to as macrophages
are CD45highF4/80+. In order to determine percent infected cells, EC and mock infected
histograms of gp70 staining were overlayed and the point at which the graphs intersected was
determined. And events falling above that point gated accordingly and considered positive. This
gate was also used to determine positive cells in the microglia population. Percent above
background was calculated by taking the average EC infected positive percentage and
subtracting from the average mock infected positive percentage.
3.9: Histology and Immunohistochemistry
Tissues sections were processed and embedded in paraffin and 4 um slides cut at the
Louisiana State University School of Veterinary Medicine Histology Laboratory. Slides were
incubated at 56oC overnight to adhere the tissue to the glass. Sections were incubated twice in
xylenes for fifteen minutes to remove residual paraffin and rehydrated with five minute
incubations in 100%, 95%, 70% ethanol, and twice in PBS. Antigen retrieval was performed
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using sodium citrate antigen retrieval buffer in a decloaking chamber (Biocare Medical,
Concord, CA) set at 120oC for 20 minutes and cooled to 90oC. Pressure consistently read
between 12-15 psi. When slides reached 90oC, they were rinsed four times with ultra pure water
by replacing half of the volume of antigen retrieval solution with water. Slides were then
washed twice with 0.5% fish skin gelatin (Sigma)/ PBS (0.5% FSG/ PBS) for ten minutes on a
rocker. To reduce potential nonspecific antibody binding due to extraneous protein-protein
interactions, slides were incubated in a humidity chamber (Fisher, Hampton, NH) in 175 µl
normal donkey serum blocking solution for at least 30 minutes. All incubations were done in a
humidity chamber and slides were covered with parafilm coverslips. Parafilm coverslips were
removed and excess blocking solution was tapped off. Slides were incubated overnight at 4oC
with goat polyclonal anti-gp70 at 1:500 in 0.5% FSG/PBS. Slides were then tapped off to
remove excess primary antibody and washed twice in 0.5% FSG/PBS for at least ten minutes
each. A biotinylated rabbit anti goat secondary antibody (Molecular Probes) was applied at a
dilution of 6.67µg/ ml in 0.5% FSG/PBS and each slide was covered with a parafilm coverslip
and incubated for at least 30 minutes at room temperature. After incubating, slides were washed
twice in 0.5% FSG/ 1x PBS. Streptavidin conjugated to AlexaFluor 594 (Molecular Probes) was
used for detection at 4 µg/ ml diluted in 0.5% FSG/PBS and incubated for 30 minutes. Slides
were washed twice in 0.5% FSG/ 1x PBS and reblocked in normal donkey serum blocking
solution for at least thirty minutes. Polyclonal rabbit anti- Iba1 (Wako) was applied to the slides
at 2.5 µg/ ml and either allowed to incubate at 4oC overnight or for at least 30 minutes at room
temperature. Following two washes for at least 10 minutes in 0.5% FSG/PBS, an AlexaFluor
488 (Molecular Probes) goat anti-rabbit secondary antibody was applied at 6.67 µg/ ml and
incubated at room temperature for at least 30 minutes. Slides were washed twice for at least 10
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minutes in 0.5% FSG/PBS and counterstained with 100 ng/ ml DAPI (Molecular Probes) for up
to 25 minutes and washed once in 0.5% FSG/PBS. Slides were mounted with ProLong Gold
antifade reagent (Molecular Probes) and allowed to set for at least two hours at 4oC to allow for
maximum effectiveness of the antifading properties.
3.10: RNA Processing for Real Time PCR
Isolation: Tissues were removed from storage at -80oC and placed in a precooled TropiCooler set at -19oC and were homogenized in 2 ml Trizol (Invitrogen) in a sterile dounce
homogenizer, pestle size B. The homogenate was split between 1.5 ml centrifuge tubes, and the
homogenizer was rinsed with 1 ml Trizol with the wash discarded. Homogenates sat at room
temperature for 5 minutes to allow for complete dissociation of nucleoprotein complexes, and
200 µl of chloroform was added to each tube. Tubes were vigorously agitated and incubated at
room temperature for 2-3 minutes. Samples were centrifuged at 12,000 x g for 15 minutes at 4oC
in an Eppendorf table-top centrifuge to separate the phases. The colorless aqueous phase
containing the RNA was removed and placed in a new 1.5 ml centrifuge tube. RNA was
precipitated using 600 µl of isopropanol and incubating the samples at room temperature for at
least ten minutes. Samples were centrifuged at 12,000x g for 10 minutes at 4oC. The RNA
formed a cloudy pellet at the bottom of the tube. Supernatants were poured off; 1 ml of 70%
ethanol was added; samples were vortexed briefly to dislodge the pellet, and centrifuged at 7,500
x g for 5 min at 4oC. Ethanol was poured off; pellets were air dried for 5-10 minutes, and 50 µl
of RNAse-free water was added to the pellets. After incubating at 55oC for 10 minutes on a dry
heat block, samples were centrifuged briefly and stored at -80oC.
DNase Treatment: After Trizol purification, RNA was then DNAse treated to remove any
residual genomic DNA from the purified RNA. A master mix was made from the Ambion
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DNase I kit by combining 10 µl DNase buffer, 15 µl (30 units) of DNase I, and 70 µl RNasefree water for each sample to be treated. 95 µl of the master mix was added to a clean 1.5 ml
centrifuge tube along with 10 µg of the appropriate RNA sample. Samples were mixed by
pipetting up and down, centrifuged briefly, and incubated at 37oC for 30 minutes. RNA was
removed using a Zymo RNA Clean-up Kit. 400 µl of RNA-Binding buffer was added to the
sample and pipetted up and down to mix. Mixture was transferred to a Zymo-spin column and
centrifuged for 30 seconds at full speed. RNA was washed twice with 350 µl of wash buffer and
centrifuged at full speed for 30 seconds before eluting in 50 µl of RNase- free water. Samples
were spun briefly and the eluate was stored at -80oC or used immediately for reverse
transcription.
Reverse Transcription: A master mix was made using Bio- Rad’s iScript cDNA Synthesis
Kit containing 10 µl nuclease-free double distilled water, 4 µl of 5x iScript Reaction Mix, and 1
µl iScript reverse transcriptase (iScript RT) for each sample. An additional 1 µl of water was
used in place of the iScript RT for the non-reverse transcribed (no-RT) controls. Approximately
1 µg of the appropriate RNA sample was added to 15 µl of master mix in a 0.5 ml tube
15 µl of this was dispensed to the bottom of a 0.5 ml centrifuge tube. Mixes of RNA were made
and serially diluted 1:5, 1:25, and 1:125 to gauge the efficiency and sensitivity of the reverse
transcription process. Tubes were placed in an MJ Research PTC Thermal Cycler and run under
the following conditions: 25oC for 5 minutes, 42oC for 30 minutes, 85oC for 5 minutes, and 20oC
forever. Upon finishing the program, samples were briefly centrifuged, 80 µl of nuclease free
water was added to each, vortexed, and centrifuged. cDNA was stored at -20oC until use.
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3.11: Real Time PCR
A master mix was made using iTaq SYBR Green Supermix with Rox containing 17.5 µl
2x iTaq SYBR Green Supermix with Rox, 1.75 µl of forward and reverse primers (1.8 µM final
concentration) and 9 µl Rnase free H2O for a total volume of 30 µl per sample. This was
dispensed into one well of a 96 well PCR plate kept in a cooler block. 5 µl (10 ng) of cDNA or
water was added to the appropriate well, the plate was covered with Rnase/ DNase free film,
vortexed to mix and centrifuged at 1500 rpm for 5 minutes. Film was removed and samples
were dispensed in triplicate into a 384 well plate (Applied Biosystems) using a Matrix electronic
repeating pipette (Matrix Technologies) Plates were spun at 1500 rpm for 5 minutes and kept at
4oC until analysis on an Applied Biosystems 7900 and acquired with SDS 2.2.2 (Applied
Biosystems). Primers for real-time PCR analysis are were designed using Primer3 software.
Specificity was confirmed by blasting the primer pairs against the National Center for
Biotechnology Information (NCBI) website. Absence of genomic DNA contamination was seen
by running reactions without reverse transcription. Non-reverse transcribed samples were either
negative for all genes after 40 cycles or had at least 1,000 fold lower expression. Gene
expression was quantified using the cycle number at which each sample reached a fixed
fluorescence threshold (CT). Data are presented as the percent difference in CT value (log2) of
each sample subtracted from its Gapdh CT value (ΔC T= CT Gapdh-CT gene of interest). This
controls for variations in RNA concentrations between each sample. Primers are shown in
Table 2.
3.12: Statistical Analysis
All statistical analysis was performed using GraphPad Prism software (San Diego, CA).
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Table 2: Primers used in this study listed by gene.
Gapdh
Fb29gag
F480
Gfap
Aif1
Cd68
Cd80
Cd86
Tnf
Tnfsfr1a
Tnfsfr1b
Tradd
Traf2
Tnfsfr6
Fadd

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

TGCACCACCAACTGCTTAGC
TGGATGCAGGGATGATGTTC
CCCGTGGCGGATTCTACT
TCGGAGAAAGAGGGGTTGTTA
ACAAGTGTCTCCCTCGTGCT
AACATGGTGCTTTCCACAGTC
CGTTTCTCCTTGTCTCGAATGAC
TCGCCCGTGTCTCCTTGA
GCCTAAGACAACCAGCGTCT
GACGGCAGATCCTCATCATT
ACCACCAGTCACGGAAATGT
CCAACAGTGGAGGATCTTGG
CCTTGCCGTTACAACTCTCC
CAGGCCCAGGATGATAAGAG
CTCCTCCTTGTGATGCTGCT
GCCTTCACTCTGCATTTGGT
CCACCACGCTCTTCTGTCTAC
GAGGGTCTGGGCCATAGAA
GCTGACCCTCTGCTCTACGA
CCATCCACCACAGCATACAG
GCATCGTGAACGTCTGTAGC
GACGGACACTCCTCCTGAGA
GGTGGAGCCATACAGGTAGC
AAGAGTCAGTGGCCGGTTC
GGCTGTGGCAAGAAGAAGAT
TAGGGCTAGGTGTTCCCGTA
GAATTACCCATGTCCCCAGA
CTCTAGGCCCACAAGATGGA
GATGGATGGGATTGAGGAGA
CTCACAGATTCCTGGGCTTC
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Chapter 4: Results
4.1: Microglia/Macrophage Related Genes Are Upregulated in the Brain During EC Virus
Infection
Previous studies demonstrated an increase in Tnfa and F480 mRNA expression in the
brains of EC infected mice as compared to mock infected controls5. Additionally, analysis of
microglia and macrophages by immunohistochemical staining show increased immunoreactivity
when stained with a microglia/macrophage specific antibody (Iba1) in EC infected mice (Fig. 4).
Iba1 and antibodies directed toward the virus envelope protein colocalized on the surface of the
same cells (Fig. 4E, yellow color) indicating that microglia and macrophages are infected with
EC.
To determine if EC infection altered the expression of TNFα receptors, or costimulatory
molecules normally expressed on microglia/macrophages, we analyzed brain tissue from infected
mice at 28 dpi, a time point at which clinical disease begins to develop. Cd86 mRNA levels
were significantly increased in the brain of EC infected mice when compared to mock infected
controls with slight but not significant increases observed in Cd80 and Cd68 mRNA (Fig 5) .
mRNA for TNFα receptors CD120a (TNFR1, p55, Tnfsfr1a) and CD120b (TNFR2, p75,
Tnfsfr1b) was also increased. This suggests that microglia and macrophages may upregulate
these molecules in response to EC infection.
4.2: Cell Enrichments From TNF-/- Animals Yielded More Microglia Than Mock Infected
Controls Early in Infection
To examine the expression of costimulatory molecules and TNFα receptors directly on
microglia/macrophages, we enriched for these cell types with Percoll gradients and analyzed for
cell surface expression by flow cytometry. The time points were chosen because the virus has
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Figure 4: EC infected mice have a higher number of activated microglia/macrophages at 28 dpi.
Animals were inoculated as described in the Materials and Methods. At 28 dpi, brains were
removed and fixed for 48 hours in 3.7% neutral buffered formalin. Sections were cut and
mounted on slides for immunohistochemical analysis. Antigens were retrieved using citrate
target retrieval with a combination of temperature and heat in a decloaking chamber. Sections
were stained with rabbit anti Iba-1 48 with an AlexaFluor 488 secondary for green fluorescence.
DAPI was used as a counterstain (blue fluorescence). Images were visualized with a Leica
microscpope and captured with a digital camera. Cerebellum of a mock infected WT mouse at
(A) 200x and (B) 400x. Cerebellum of an EC infected WT mouse at (C) 200x and (D) 400x. (E)
Slides from an EC infected WT mouse at 28 dpi were also incubated with goat anti-gp70 with a
biotinylated anti-goat secondary applied and visualized with streptavidin conjugated AlexaFluor
594 (400x). Dual labeling is seen as yellow.
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Figure 5: Genes upregulated during EC infection. Neonatal 129SvEv mice were inoculated with
104 FFU of EC within 24 hours of birth. At 28 dpi, brain tissue from mock (n=3) and EC (n=5)
infected was removed with sagittal halves flash frozen for RNA isolation and cDNA production
as described in the Materials and Methods. mRNA expression was determined using
quantitative real time PCR with samples run in triplicate. Data are presented as the expression of
the gene of interest as a % of Gapdh mRNA expression. Statistical analysis was done using a
one-way ANOVA with the Neuman-Keuls post-test.
established the infection by 14 dpi, and WT animals begin to show symptoms of the neurological
disease at 28 dpi. Microglia and macrophages were identified by their relative expression of
CD45, F4/80, and CD11b41,77. In agreement with previously reported findings, microglia and
macrophages in this study exhibited the typical staining pattern of CD45high F480+ CD11b+
macrophages and CD45low F480+ CD11b+ microglia41,77. For further analysis, samples were
gated as described in the Materials and Methods and shown in Fig. 6. Cells from mock infected
TNF-/- and WT mice expressed similar levels of CD45, F4/80 and CD11b at both time points
analyzed. Surprisingly, EC virus infection had a negligible effect on the expression of these
features at both time points. However, infection with EC did appear to raise the number of
microglia enriched from the brain with the largest difference seen in TNF-/- mice at 14 dpi (Fig.
7) whereas the number of macrophages was consistent for each strain at both time points.
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Figure 6: Separation microglia and macrophage populations by their relative expression of
CD45. Microglia and macrophages were enriched from the brain tissue of a 28 dpi WT mouse
using Percoll gradients and subsequently analyzed by flow cytometry. Cells were incubated with
the proper dilution of directly conjugated primary antibody, washed, and fixed in
paraformaldehyde before analysis. Cellular debris was gated out of the analysis based on
previous ViaProbe staining for viable cells. The graph presented is representative of multiple
experiments. Events falling within quadrant II were designated CD45high F4/80+and those
falling within quadrant III as CD45low F4/80+. Macrophages exhibit a CD45high F4/80+ staining
pattern whereas microglia are CD45low F4/80+. Similar gating criteria was used in all
subsequent analyses.
Percent of Total Population

Microglia, 14 dpi
95
90
85
80
75
70
65
60
55
50

WT Mock

WT EC

TNF Mock

TNF EC

Group

Figure 7: At 14 dpi, TNF-/- animals have a lower proportion of CD45low F480+ cells. Neonatal
TNF-/- and wild-type control mice were infected with 104 FFU of EC within 24 hours of birth.
Cells were enriched for and analyzed as described in the Materials and Methods. Data are
presented as the percent of cells within the FSC vs. SSC gate that exhibit the F480+ CD45low
staining pattern. Each symbol represents one animal. A siginificant decrease by a one way
ANOVA with Neuman-Keuls post hoc tests was seen mock infected TNF-/- mice compared to
the other groups (P<0.001), whereas there was no difference between or among the WT groups.
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4.3: Macrophages and Not Microglia Are Predominantly Infected With EC
Both microglia and macrophages are potential targets of EC infection. Virus infection
may influence activation and the subsequent release of potentially damaging factors. At both
time points tested, microglia and macrophages enriched from WT and TNF-/- mice tested
positive for the viral glycoprotein gp70 (Fig 8). At 14 dpi, 38% of macrophages enriched from
EC infected WT mice were positive for virus as compared to 27% from EC infected TNF-/mice. Surprisingly, virus was undetected in microglia enriched from either WT or TNF-/- mice
(0.67% and 0.30% above background, respectively). At 28 dpi, 36% of from WT and 41% from
TNF-/- mice were positive for virus, indicating similar levels of virus infected macrophages. A
substantial increase in microglia infection was observed at 28 dpi, with 1.23% of WT and 5.01%

Figure 8: Macrophages were predominantly infected with EC early in infection, with more
microglia staining for the virus protein by 28 dpi. Microglia and macrophages were enriched and
analyzed from (A) WT and (B) TNF-/- mock and EC infected brains as described in figure 7.
Cells were incubated in a polyclonal goat anti- gp70 primary antibody followed by rabbit antigoat AlexaFluor 488 (Molecular Probes) to visualize the staining.
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of TNF-/- microglia cells positive for the virus. This suggests that the virus infection starts in the
macrophage population of the brain and it slowly spreads to microglia, indicating that
macrophages more than microglia may serve as a reservoir for further virus infection in the
brain.
4.4: Expression of Activation Features During EC Infection
Activation of microglia and macrophages has been associated with both neuroprotection
and neuropathogenesis5,78,79. Previous studies indicate a potential role for TNFα in the activation
of microglia/macrophages5,32,33,78,79. To determine if systemic TNFα deficiency has a detectable
effect on the activation of these cell types during EC infection, we analyzed the expression
CD68, CD80 and CD86 which are often upregulated on macrophages/ microglia following
activation78,80. At both time points tested, markers were present and expressed at similar levels
on microglia and macrophages enriched from mock infected WT and TNF-/- mice, with a
slightly higher level of expression of CD86 on macrophages than microglia (Fig. 9, 14 dpi; Fig.
10, 28 dpi). No difference in the geometric means or mean channel numbers was observed
between WT and TNF infected mice (Tbl. 3, 4). Expression of CD68, CD80 and CD86 was
unchanged in TNF-/- or WT mice following EC infection at 28 dpi (Fig. 10), indicating that EC
virus infection may not induce significant upregulation of these molecules.
4.5: TNFα Receptor Expression on Microglia/Macrophages
TNFα signaling has various outcomes depending on which of its two receptors it
activates. Signaling through CD120a is associated with the proteotypic inflammatory responses
and is usually initiated by secreted TNFα (rev. in 19). The results of CD120b signaling tend to be
tissue specific due its affinity for membrane bound TNFα(rev. in 19). Microglia and
macrophages expressed both TNFα receptors at each time point tested (Fig. 9, 14 dpi; Fig. 10, 28
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Table 3: Average geometric means for the phenotypic features of macrophages and microglia that were analyzed by flow cytometry.
Cells were enriched and analyzed as described in Figure 5. Antigen specific geometric means from the total macrophage or total
microglia population were determined by FlowJo Software. Data from at least two separate experiments were used in the calculations.
(a) mean, (b) range.
Stra in Inoculation DPI

Cell Type

WT
WT
TN F
TN F

Mock
EC
Mock
EC

14
14
14
14

M acrophage
M acrophage
M acrophage
M acrophage

WT
WT
TN F
TN F

Mock
EC
Mock
EC

14
14
14
14

WT
WT
TN F
TN F

Mock
EC
Mock
EC

WT
WT
TN F
TN F

Mock
EC
Mock
EC

Value

CD11b

CD68

CD80

CD86

CD120a

CD120b

GM 1027
GM
824
GM 1,185
GM
861

± 298.0
± 244.0
± 258.0
±
17.8

500
573
434
418

± 139.0 64.7 ± 7.4 46.6
± 224.0 66.7 ± 12.6 46.5
± 33.0 115.0 ± 19.2 89.1
± 35.0 122.0 ± 42.1 114.0

±
±
±
±

14.5
15.2
2.4
22.4

6.7
6.8
7.5
7.1

±
±
±
±

0.9
1.0
1.3
1.1

39.8
35.8
39.8
39.6

± 20.2
± 16.4
± 4.3
± 4.9

M icroglia
M icroglia
M icroglia
M icroglia

GM
GM
GM
GM

253
239
310
290

±
±
±
±

200
188
204
190

±
±
±
±

28
28
28
28

M acrophage
M acrophage
M acrophage
M acrophage

GM
GM
GM
GM

1,445
1,007
311
495

±
±
±
±

28
28
28
28

M icroglia
M icroglia
M icroglia
M icroglia

GM
GM
GM
GM

399
394
313
336

±
±
±
±

29.0
47.0
48.0
11.0

39.0
54.0
11.0
40.0

10.9
10.5
9.1
9.4

±
±
±
±

2.1
2.7
0.7
0.3

28.7
28.7
31.3
31.4

±
±
±
±

3.5
3.8
1.4
1.8

5.1
5.0
5.0
4.8

±
±
±
±

0.3
0.3
0.3
0.1

25.8
25.2
19.7
21.4

± 13.5
± 12.4
± 1.1
± 9.6

234.0 1276 ± 655.0
192.0 1457 ± 429.0
29.0 381 ± 44.0
73.0 265 ±
3.0

30.1
33.1
32.4
35.1

±
±
±
±

2.2
1.9
3.4
5.4

22.3
26.3
30.4
37.1

±
±
±
±

0.8 7.7
4.3 6.8
0.9 8.8
1.1 11.3

±
±
±
±

0.2
1.4
1.2
0.1

22.1
23.5
18.5
27.4

±
±
±
±

13.6
12.9
13.1
12.6

± 8.3
± 6.3
± 11.8
± 17.3

22.2
22.5
23.5
26.8

± 174.7
± 190.2
±
3.1
± 29.8

± 3.3
± 23.6
± 14.7
± 1.2

7.7
7.3
8.1
8.6

18.0
21.0
11.0
24.0

157
163
197
140

±
±
±
±

33

63.1
33.7
11.3
1.2

7.7
7.3
8.1
8.6

2.2
3.9
1.5
1.7

± 0.3
± 18.3
± 8.9
± 6.8

Table 4: Average mean channel numbers for the phenotypic features of macrophages and microglia that were analyzed by flow
cytometry. Cells were enriched and analyzed as described in Figure 5. Antigen specific mean channel numbers from the total
macrophage or total microglia population were determined by FlowJo Software. Data from at least two separate experiments were
used in the calculations. (a) mean, (b) range.
Stra in Inoculation DPI

Cell Type

Value

CD11b

WT
WT
TN F
TN F

Mock
EC
Mock
EC

14
14
14
14

M acrophage
M acrophage
M acrophage
M acrophage

M CN
M CN
M CN
M CN

253
240
310
290

WT
WT
TN F
TN F

Mock
EC
Mock
EC

14
14
14
14

M icroglia
M icroglia
M icroglia
M icroglia

M CN
M CN
M CN
M CN

WT
WT
TN F
TN F

Mock
EC
Mock
EC

28
28
28
28

M acrophage
M acrophage
M acrophage
M acrophage

WT
WT
TN F
TN F

Mock
EC
Mock
EC

28
28
28
28

M icroglia
M icroglia
M icroglia
M icroglia

CD68

CD80

CD86
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Figure 9: Microglia and macrophages enriched from mock and EC infected WT (A) and TNF-/(B) mice at 14 dpi have similar expression of the markers CD80, CD86, CD120a, and CD120b.
Microglia/macrophages from the brains of mice were enriched via Percoll gradients with the
microglia/macrophage fraction residing between the 70% Percoll layer and the 37% isotonic
Percoll layer. The residual brain tissue was removed before the microglia enriched fraction was
harvested. The microglia/macrophages were then stained for cell surface markers to determine
the purity of the fraction and for phenotypic analysis as described in figure 5. Data was collected
on a FACSAria and analyzed with FlowJo software.
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Figure 10: Expression of activation markers and TNF receptors at 28 dpi on macrophages and
microglia was similar to that seen at 14 dpi. Microglia and macrophages were enriched and
analyzed from (A) WT and (B) TNF-/- mock and EC infected brains as described in Figure 9.
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dpi). Interestingly, neither the absence of TNFα or EC infection altered their expression on these
cell types.
4.6: Minocycline Treatment Had No Effect on Delaying the Onset of Neurological Disease.
EC infection is known to induce Tnfa mRNA production and microglia/macrophage
activation as measured by mRNA expression of F48072. To determine if inhibiting TNFα
production and microglia/ macropage activation during an established viral infection would
impede the development of neurological disease, we treated mice with minocycline which has
the ability to decrease microglia/macrophage activation and TNFα2. Treatment was initiated at
14 dpi using a previously described concentration81. This will allow the virus an opportunity to
establish a productive infection in the brain prior to treatment. Surprisingly, there was no
statistical difference in survival curve analysis between the EC infected placebo and minocycline
treated groups (Fig. 11), indicating that minocycline could not prevent EC induced disease.

Survival Curve: Minocycline Treatment
Percent diseased/dead

100

Mock PBS
Mock Mino
EC PBS
EC Mino

75
50
25
0
0

25

50

75

100

125

150

dpi

Figure 11: Administration of minocycline does not alter EC mediated disease. Mice were
infected as described in figure 2. At 14 dpi, litters were randomly assigned a treatment regimen
that consisted of one ip injection of 25 µl phosphate buffered saline (PBS) or 35 mg/kg
minocycline in 25 µl PBS every other day. Animals were observed daily for obvious signs of
neurological disease characterized by ataxia, hind limb paralysis or seizures. Data are presented
as percent of mice exhibiting severe neurological disease for 16 Mock PBS, 20 Mock
minocycline, 22 EC PBS and 21 EC minocycline mice. Statistical analysis was performed with a
Kaplan-Meier survival test using GraphPad Prism.
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4.7: Effect of Minocycline Treatment on Virus Levels, Microglia/Macrophage and
Astrocyte Activation.
Despite the lack of an influence on neurological disease, minocycline treatment may
influence viral replication, microglia/macrophage activation and/ or TNFα production2,31. At 28
dpi, brain tissue was removed for quantitative real time PCR analysis of mRNA expression. We
examined mRNA expression of genes that are upregulated during EC induced neurological
disease to determine of minocycline treatment had an effect on their mRNA expression.
Surprisingly, minocycline treatment did not alter the mRNA expression of microglia/macrophage
markers F480 or Aif1 (Fig. 12B, 13A). There was a slight, but not statistically significant,
decrease in both Fb29gag and Gfap (Fig. 12A, C) indicating that treatment may have slightly
reduced viral load and astrocyte activation during EC infection.

Figure 12: Genes corresponding to virus load and astrocyte activation were slightly decreased in
the EC infected minocycline treated animals. Brain tissue was removed from PBS and
minocycline treated mock and EC infected animals at 28 dpi and processed for real-time PCR as
described in the Materials and Methods. Data are presented as the expression of the gene of
interest as a percent of Gapdh mRNA expression. Statistical analysis was done using a one-way
ANOVA with the Neuman-Keuls post-test. For mock infected PBS and minocycline treated
groups n=3, and both EC infected groups had an n=5. All groups are composed of animals from
multiple litters.
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mRNA expression of Aif1, Cd80, Cd86, and Cd86 were not altered by minocycline (Fig. 13).
Thus, minocycline did not substantially influence mRNA expression of microglia/macrophage
activation molecules or those associated with EC virus infection

Figure 13: EC infection correlates with the increase in microglia activation genes Aif1 (A) and
Cd86 (D). Samples were collected and processed as mentioned in Figure 11. The genes are as
follows: Aif1 (A), Cd68 (B), Cd80 (C), and Cd86 (D). Statistical analysis was performed using a
one-way ANOVA with the Neuman-Keuls post-test. For mock infected PBS and minocycline
treated groups n=3, and both EC infected groups had an n=5. All groups are composed of
animals from multiple litters. Where indicated, * denotes p<0.05 and ** denotes p<0.01.
4.8: Minocycline Treatment Influences mRNA Involved in Signaling Within the TNF
Superfamily
In addition to decreasing microglia/macrophage activation, minocycline treatment is
associated with decreased TNFα expression2. EC infection did increase Tnfa mRNA in PBS and
minocycline treated groups and that minocycline reduced Tnfa mRNA in EC infected mice albeit
at a statistically insignificant level (Fig. 14A). This agrees with previous studies showing Tnfa
mRNA upregulation only in localized areas of the brain following EC infection5. To determine

39

Figure 14: Expression of Tnfa (A) Tnfsfr1a (B), Tnfsfr1b (C), Traf2 (D), Tradd (E), Cd95 (F),
and Fadd (G) during minocycline treatment. Brain tissue was removed from PBS and
minocycline treated mock and EC infected animals at 28 dpi and processed for real-time PCR as
described in the Materials and Methods. Data are presented as the expression of the gene of
interest as a percent of Gapdh mRNA expression. Statistical analysis was performed using a
one-way ANOVA with the Neuman-Keuls post-test. For mock infected PBS and minocycline
treated groups n=3, and both EC infected groups had an n=5. All groups are composed of
animals from at least two litters. Where indicated, * denotes p<0.05 and ** denotes p<0.01.
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if minocycline treatment had an effect on genes involved with signaling, we analyzed the mRNA
levels for receptors and adaptor molecules within this family. Treatment with minocycline
significantly lowered the basal level expression of Traf2, Tradd, and Cd95 (Fig. 14D, E, F). EC
infection in PBS treated animals led to an increase in Cd120a, Cd120b, Traf2, Cd95, and Fadd
(Fig. 14B, C, E, F, G). Interestingly, minocycline treatment during EC infection reduced the
expression of CD120b, Traf2, Cd95, and Fadd (Fig. 14C, E, F, G). The finding of decreased
Tradd and Traf2 mRNA may be important in understanding how minocycline may potentially
influence the TNF signaling cascade through the expression of accessory molecules or receptor
expression.
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Chapter 5: Discussion
In the current study, we analyzed the influence of TNFα on the activation phenotype of
microglia and macrophages and the expression of genes associated with TNFα signaling and
microglia/macrophage activation in animals treated with minocycline during EC infection.
Activation features were present and expressed at similar levels on microglia and macrophages
enriched from mock infected WT and TNF-/- animals, with a higher level of expression of CD86
on macrophages. These markers were unchanged on microglia or macrophages by EC infection
in both WT or TNF-/- mice. Thus, neither systemic absence of TNFα or EC infection
dramatically altered the phenotypic profiles of these cells. Administration of minocycline to
inhibit microglia/macrophage activation had no statistically significant effect on delaying the
onset of neurological disease during EC infection. However, minocycline may alter the course
of TNFα signaling as it interferes with mRNA expression of TNFα receptors and signaling
molecules, this therefore may inhibit signal transduction.
Real time PCR analysis at 28 dpi showed an increase in Cd80, Cd86, Cd120a and
Cd120b mRNA from the whole brain indicating an upregulation of costimulatory molecules and
TNF receptors in EC infected mice (Fig. 5). Microglia and macrophages enriched from mock
infected WT and TNF mice did test positive for these markers, but there was no detectable
increase in expression in response to EC infection on the surface of these cells (Fig. 9, 10). It is
possible that a subset of highly activated macrophages and microglia with increased expression
of these markers did not survive the enrichment process. Alternately, another cell type may be
responsible for the elevated levels of mRNA of these markers observed in EC infected mice. For
example, dendritic cells may be recruited to the brain, become activated in response to EC
infection and upregulate expression of CD80 and CD8682. Reactive astrocytes also have been
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shown to express these molecules on their cell surface and could contribute to the elevated levels
of Cd80 and Cd86 mRNA83.
The disparities between the upregulation of genes by real-time PCR but not by flow
cytometric analysis may be attributed to differences with the technique. It is possible that the
mRNA increase observed at 28 dpi precedes protein expression on the surface of the cell, thereby
explaining the discrepancies between the flow and real- time PCR data. Real- time PCR analysis
can detect small alterations in gene expression with high fidelity can be significant due to its
sensitivity and reproducibility whereas flow cytometric analysis lacked the ability to do so. One
of the limitations of real- time PCR analysis of a total tissue is that gene expression from a
specific cell population cannot be identified. Once a gene of interest has been identified, then in
situ hybridization could be a potential next step to determine the cell type and location in the
brain where the gene is expressed. Alternately, mRNA from FACS sorted microglia and
macrophages could be purified for gene analysis of activation features. The result could then be
directly compared to the surface expression of the molecule to determine if RNA expression in
that very specific cell population correlated with the protein expression.
A current theory in regards to HIV-1 associated dementia suggests that increased
trafficking into the brain of infected monocytes late in the course of infection may be the first
step in clinical HAD84. A similar situation may be occurring during EC infection, where EC
appears to infect macrophages in the brain prior to detectable microglia infection at 28 dpi.
Histolgical examination of tissues dual-stained for Iba1, a microglia/macrophage marker, and
gp70, a virus envelope protein, indicates that the virus infected cells were in brain tissue rather
than in circulation (Fig. 4). In the early stages of EC infection, infected monocytes may migrate
to the brain where the virus infection spreads among resident macrophages and microglia. It is
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also possible that the endothelial cells lining the blood vessels in the brain become infected first.
The virus may then spread to perivascular macrophages and then to nearby microglia. The
increase in microglia numbers enriched from EC infected TNF-/- mice (Fig. 7) suggests that this
population may be expanding possibly in response to the viral insult. This rapid increase in cell
number may explain the increase in infection rate seen in the microglia population for
retroviruses utilize machinery from an actively dividing cell in order to replicate85.
TNF-/- mice grow and develop as a normal WT mouse, but these animals lack follicular
dendritic cell networks and germinal centers that are important for B cell development86. It is
unlikely that the lack of germinal centers could contribute to the reduced number of infected
macrophages in the brain of TNF-/- mice, but it is possible that the absence of follicular dendritic
cell networks could potentially slow the spread of the viral infection to macrophages in the
peritoneum. In addition, another possible explanation for the large number of infected
macrophages versus microglia in the brain could be due to receptor expression. Polytropic
retroviruses utilize XPR-1 to mediate entry into the cell, and it could be that macrophages
express the receptor at a higher level making them potentially more susceptible to infection.
Minocycline’s beneficial influence upon neuroinflammation has been shown in multiple
models of neurological disease including reovirus infections, Huntington’s disease, Alzheimer’s
disease, and SIV58,60,61,63,81. Mincycline treatment is often associated with decreased microglial
activation and TNF secretionα2,65,66,81,82. In the current study, minocycline did not confer any
benefit in terms of delaying the onset or decreasing the incidence of neurological disease (Fig.
11). It is possible that a higher dose could have possibly had an effect on the onset of EC
induced neurological disease. However, the dosage used in this study has been successfully used
to observe differences in the onset of neurological disease in viral induced encaphilitis81 when
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given concurrently with infection. Additionally, a single treatment of minocycline has been
effective in decreasing microglial activation87. Previous studies with minocycline are usually
undertaken in an adult animal model of disease, whereas this model utilizes neonatal infection.
Treatment of neonatal mice with minocycline is lethal (unpublished observation), so
administering the first treatment either prior to or concurrently with infection is not possible in
this model. Also, infection cannot be delayed due to the fact that mice need to be inoculated
with the virus within one day of birth for optimal disease development88. It may be that
minocycline treatment is ineffective in already established or slowly progressing viral diseases.
This could be to the slow rate at which the virus spreads to the brain, or that the virus has already
initiated the chain of events that induces pathogenesis. It would be of interest to determine if
minocycline treatment could delay disease in another retrovirus model that does not require
neonatal inoculation, so that the system could be primed by a pretreatment with minocyline or
administered at the time of infection.
Decreased microglial activation during minocycline treatment has been measured by
different methods including decreased proliferation during treatment, or decreased IL-1β or
TNFα secretion2,63,65,81. However, analysis of genes associated with microglia and macrophage
activation had yet to be performed. Minocycline had no effect on decreasing mRNA expression
of F480, Aif1, Cd80, Cd86, Cd120a or Cd120b (Fig. 12B, 13A, 13C, 13D, 14B, 14C) in the
brains of mock infected mice but we did find decreased expression of Tradd and Traf2 in both
the mock and EC infected treated groups. The finding of decreased mRNA Tradd and Traf2
mRNA may be important in understanding how minocycline could influence the TNF signaling
cascade not only in this model but also for other models that may utilize this drug to inhibit
TNFα.
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The ability of minocycline to decrease TNFα secretion in microglia cultures in vitro has
been well established2,64, but the question remains as to how this influences the bigger picture of
TNF signaling in vivo. TRAF2 interacts with death and non-death domain containing receptors
of the TNF Superfamily: CD120a and CD95 (death) and CD120b (non-death). Due to its lack of
a death receptor, CD120b can bind directly to members of the TRAF family whereas CD120a
involves TRAF2 indirectly through interacting with TRADD which will bind to TRAF2
(reviewed in 89). The subsequent signaling cascade induced by TRAF2 recruitment is regulated
by molecules that to interfere with the process by blocking protein interactions or modifying the
composition of the complexes25. TRADD mediated signaling usually results in apoptosis,
whereas signaling through TRAF2 is often associated with cell survival. Under normal
circumstances, inhibiting TRAF2 may potentially be detrimental to the host for this protein often
mediates anti-apoptotic events25,90. During HIV infection, one of the downstream effects of
TRAF2 mediated signaling is the activation of viral genome transcription91. Minocycline could
possibly reduce HIV transcription by decreasing the level of Traf2 mRNA in the host cell, but
this could inadvertently push non-target cells to signal through TRADD and predispose them to
apoptosis. Although it is possible that through minocycline’s ability to inhibit both Traf2 and
Tradd mRNA expression that the negative effects of reducing either of these alone may be
negated.
In addition to potentially modulating TNFα signaling, minocycline treatment may have
an additional and as yet recognized role in downregulating Cd95 mRNA expression in the brain.
Mock infected minocycline treated mice showed a significant decrease in Cd95 mRNA
expression as compared to their PBS treated controls (Fig. 14F). EC infection did increase
expression of this gene in minocycline treated groups but not to the extent observed in the EC
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infected PBS treated group. Fadd expression was also decreased in EC infected minocycline
treated animals (Fig. 14G) suggesting the drug may influence downstream signaling further. The
CD95- CD95L system has been associated with a variety of neurological diseases including both
human and murine retrovirus infections of the CNS27,28. In addition to this, it is interesting to
speculate upon how specifically inhibiting both Fadd and Tradd mRNA expression could
influence a cell. By significantly reducing their expression, it may be possible to potentially
force a cell to be insensitive to apoptosis and promote cell survival. Understanding how to better
modulate the CD95- CD95L pathway and TNF induced apoptosis may lead to the ability to
inhibit apoptosis and decrease neuronal cell loss and potentially delay disease onset. In doing so,
this could decrease the severity of neurological disease in not solely this model but others in
which this pathway has been directly linked to pathogenesis such as in experimental autoimmune
encephalitis or Parkinson’s disease92,93.
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